Google News Follow
Watchlist

USFDA gives nod to Alembic Pharma’s generic formulation to treat itchy eyes

Alembic has a cumulative total of 216 ANDA approvals (189 final approvals and 27 tentative approvals) from USFDA.

Written by Health Desk
USFDA gives nod to Alembic Pharma's generic formulation to treat itchy eyes
The formulation is therapeutically equivalent to the reference listed drug product (RLD), Lastacaft Solution, 0.25%, of AbbVie Inc. (Image Credits: Pixabay)

Alembic Pharmaceuticals Limited on Friday announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Alcaftadine Ophthalmic Solution, 0.25% (OTC).

According to the company’s press statement, the approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Lastacaft Solution, 0.25%, of AbbVie Inc. (AbbVie).

Also Read

Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander, it added.

Alembic has a cumulative total of 216 ANDA approvals (189 final approvals and 27 tentative approvals) from USFDA.

Read Next
No surgery. No scans. Bill is $41,297″ – Viral post calls US healthcare ‘extortion’
Who is Lex Wexner? Epstein’s ‘possible co-conspirator’ named in FBI email
FDA approves daily pill version of Novo Nordisk’s weight-loss drug Wegovy – How much will it cost?
TOPICS
Alembic Pharmaceuticals
Healthcare
Pharma and Healthcare
pharmaceuticals
USFDA
+ 0 More
This article was first uploaded on October four, twenty twenty-four, at twenty-five minutes past two in the afternoon.
Market Pulse
X